Inhibition of TNF-α by the therapeutic monoclonal antibodies (infliximab, adalimumab) proved to be a breakthrough in the treatment of IBD for both, CD and UC, changed patients’ prognosis. Here, TNF is linked to inflammatory bowel disease.